Kane Biotech Unveils New Research on DispersinB®
Kane Biotech Inc. (TSX-V: KNE; OTCQB: KNBIF) has recently published an important review article about DispersinB® in the journal Pathogens. This milestone highlights the company's dedication to advancing innovation in the biotechnology field.
Details of the Publication
The article, titled "Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme," is written by Dr. Jeffrey B. Kaplan, a leading expert in the discovery of the DispersinB® enzyme. Dr. Kaplan has held esteemed positions at various respected institutions, making this publication a significant contribution to the scientific community.
Pathogens is a well-regarded international, peer-reviewed journal that focuses on the interactions between pathogens and their hosts. The findings in this manuscript reflect extensive research on DispersinB®, which has been studied in over 70 laboratories across 21 countries, including prestigious institutions like Harvard Medical School and the Mayo Clinic. Dr. Kaplan noted that DispersinB® exhibits antibiofilm activity against more than 25 bacterial species, indicating its potential as a versatile agent against biofilms.
Impact of Research Findings
With Kane Biotech's comprehensive biocompatibility testing and formulation studies involving DispersinB®, the company is optimistic about the commercial potential of future products that utilize this enzyme. This positive perspective demonstrates Kane Biotech's ongoing commitment to advancing science within the biopharmaceutical sector.
Upcoming Presentations by Kane Biotech
Alongside the recent publication, Kane Biotech is set to present ongoing research at several prestigious conferences. The company will share insights on:
- The antibiofilm properties of revyve™ Antimicrobial Wound Gel Spray, specifically designed for complex combat wounds, at the Military Health System Research Symposium (MHSRS).
- The effectiveness and compatibility of revyve™ Antimicrobial Wound Gel with various dressings at the Symposium on Advance Wound Care (SAWC).
Earlier this year, Kane Biotech showcased groundbreaking research on a novel thermo-reversible antimicrobial hydrogel spray aimed at treating complex combat wounds during the Special Operations Medical Association (SOMA) 2024 Scientific Assembly. These presentations reaffirm Kane's commitment to educating clinicians about biofilm management and the potential treatments available for chronic wound infections.
Leadership Statements
Dr. Robert Huizinga, Board Chair, remarked, "These ongoing presentations underscore Kane’s commitment to assisting clinicians in tackling the challenges posed by biofilms while unveiling possible therapeutic solutions for chronic infections." This proactive approach illustrates the company’s forward-thinking strategy in addressing critical healthcare issues.
Overview of Kane Biotech
Kane Biotech Inc. is a leader in biotechnology, concentrating on the research, development, and commercialization of technologies aimed at preventing and eliminating microbial biofilms. The company boasts an impressive intellectual property portfolio with 68 patents, along with trade secrets and trademarks that support its extensive biofilm research capabilities. Key products, including DispersinB®, coactiv+™, DermaKB™, and revyve™, are central to Kane's offerings.
Trading on the TSX Venture Exchange under the ticker symbol "KNE" and on the OTCQB as "KNBIF," Kane Biotech exemplifies a strong commitment to advancing biotechnology in the healthcare industry.
Contact Information
For further inquiries, please reach out to:
Marc Edwards
Chief Executive Officer
Email: medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
What is DispersinB®?
DispersinB® is an enzyme recognized for its antibiofilm properties and is being researched for its potential in treating chronic infections.
Who authored the recent publication?
The publication was written by Dr. Jeffrey B. Kaplan, who is known for discovering DispersinB® and is a respected scientist in the field of microbiology.
What are the main uses of revyve™ products?
The revyve™ products are designed for the treatment of complex wounds, leveraging their antimicrobial and antibiofilm properties.
At which conferences will Kane Biotech be presenting?
Kane Biotech will present at the Military Health System Research Symposium and the Symposium on Advance Wound Care.
How can I get in touch with Kane Biotech for more information?
You can contact Marc Edwards or Ray Dupuis using their respective email addresses provided above for any inquiries.
